Gastroenterology | New Developments

Allakos

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting

Lead Product(s): Antolimab

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 24, 2020

Details:

AK002, an Anti-Siglec-8 antibody, depletes tissue eosinophils and improves dysphagia symptoms in patients with eosinophilic esophagitis.

Cystic Fibrosis Foundation

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement

Lead Product(s): SNSP003

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Synspira Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 12, 2020

Details:

Synspira Therapeutics signed this agreement to support the development of SNSP003, Synspira’s orally delivered enzyme replacement therapy to treat Malabsorption Syndrome.

Codexis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic...

Lead Product(s): CDX-7108

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Nestle Health Sciences SA

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 10, 2020

Details:

The companies’ new agreement will advance the development of CDX-7108, the lead candidate for a potential treatment of a GI disorder.

Find

Find Novel Gastroenterology Drugs in Clinical Development

Undisclosed

Product Type

Companies

Allakos

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting

Cystic Fibrosis Foundation

Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement

Codexis

Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic...